Showing 1701-1710 of 5693 results for "".
Qualities a Surgeon Seeks in an OD
https://modernod.com/topics/business/qualities-a-surgeon-seeks-in-an-od/39153/What exactly are ophthalmologists looking for when hiring an optometrist?- CheckedUp Launches Virtual Visits Telehealth Platform for Specialty Carehttps://modernod.com/news/checkedup-launches-virtual-visits-telehealth-platform-for-specialty-care/2477689/CheckedUp announced the launch of CheckedUp Virtual Visits, a telemedicine system designed to improve virtual specialty care. CheckedUp Virtual Visits was created to keep patients and physicians at the center of pivotal health care decisions as “point of care” engagement evolves with pa
- Medicare Plans to Phase in Changes for Office-Visit Paymentshttps://modernod.com/news/medicare-plans-to-phase-in-changes-for-office-visit-payments/2479706/The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services, according to a Medscape
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using
- Santen Announces Topline Data for DE-128 (MicroShunt) Demonstrating Reductions in IOP and Medication Use in Patients With Glaucomahttps://modernod.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/Santen Pharmaceutical announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction. The study compared DE-128 implanted intraoperatively w
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff